Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v4-FR | Version v4-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2021-01-26 | 2021-01-26 |
| Drug Identification Number | 02139499 | 02139499 |
| Brand name | MAGNESIUM SULFATE INJECTION | MAGNESIUM SULFATE INJECTION |
| Common or Proper name | Magnesium Sulfate Injection | Magnesium Sulfate Injection |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | MAGNESIUM SULFATE | MAGNESIUM SULFATE |
| Strength(s) | 500MG | 500MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
| Packaging size | 500 mg/mL, SD Vial, 50 mL | 500 mg/mL, SD Vial, 50 mL |
| ATC code | B05XA | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2020-11-04 | 2020-11-04 |
| Estimated end date | Unknown | Unknown |
| Actual end date | 2020-12-22 | 2020-12-22 |
| Shortage status | Resolved | Resolved |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to increased demand and production delays, we will be placing this product on 50% allocation effective today, Wednesday, November 4, 2020. AND C96410P to cover 50 % of the 50 mL demand on a 5:1 ratio) UPDATE Fresenius Kabi Canada Ltd. is pleased to advise that we will be increasing the allocation placed on our Magnesium Sulfate Injection 500 mg/mL SD Vial 50 mL to 100% effective December 22, 2020. Please note that Magnesium Sulfate Injection 500 mg/mL SD Vial 10 mL remains on 100% allocation. | Fresenius Kabi Canada Ltd. regrets to advise that due to increased demand and production delays, we will be placing this product on 50% allocation effective today, Wednesday, November 4, 2020. AND C96410P to cover 50 % of the 50 mL demand on a 5:1 ratio) UPDATE Fresenius Kabi Canada Ltd. is pleased to advise that we will be increasing the allocation placed on our Magnesium Sulfate Injection 500 mg/mL SD Vial 50 mL to 100% effective December 22, 2020. Please note that Magnesium Sulfate Injection 500 mg/mL SD Vial 10 mL remains on 100% allocation. |
| Health Canada comments |